PRTC vs. ARWR, XENE, CORT, FOLD, IDYA, PTCT, MOR, MRVI, DYN, and RNA
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Arrowhead Pharmaceuticals (ARWR), Xenon Pharmaceuticals (XENE), Corcept Therapeutics (CORT), Amicus Therapeutics (FOLD), IDEAYA Biosciences (IDYA), PTC Therapeutics (PTCT), MorphoSys (MOR), Maravai LifeSciences (MRVI), Dyne Therapeutics (DYN), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical preparations" industry.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) and PureTech Health (NASDAQ:PRTC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, community ranking, institutional ownership, valuation, risk, analyst recommendations and earnings.
In the previous week, Arrowhead Pharmaceuticals had 6 more articles in the media than PureTech Health. MarketBeat recorded 8 mentions for Arrowhead Pharmaceuticals and 2 mentions for PureTech Health. Arrowhead Pharmaceuticals' average media sentiment score of 1.25 beat PureTech Health's score of 0.76 indicating that PureTech Health is being referred to more favorably in the news media.
62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 4.5% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
PureTech Health has a net margin of 0.00% compared to PureTech Health's net margin of -163.32%. Arrowhead Pharmaceuticals' return on equity of 0.00% beat PureTech Health's return on equity.
Arrowhead Pharmaceuticals currently has a consensus price target of $51.00, indicating a potential upside of 122.22%. Given PureTech Health's higher probable upside, equities analysts clearly believe Arrowhead Pharmaceuticals is more favorable than PureTech Health.
Arrowhead Pharmaceuticals has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.
Arrowhead Pharmaceuticals received 517 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 65.26% of users gave Arrowhead Pharmaceuticals an outperform vote while only 38.89% of users gave PureTech Health an outperform vote.
PureTech Health has lower revenue, but higher earnings than Arrowhead Pharmaceuticals.
Summary
PureTech Health beats Arrowhead Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
